US Bill Seeks To Eliminate Biosimilar Interchangeability Trial Burden
‘Biosimilar Red Tape Elimination Act’ Would Remove Need For Switching Studies
Sen. Mike Lee, R-UT, has introduced draft legislation in the US that would stop the FDA from requiring biosimilars to conduct ‘unnecessary’ switching studies in order to obtain an interchangeability designation.
